Contineum Therapeutics Class A Price Chart
Contineum Therapeutics Class A Volume Chart
Contineum Therapeutics Class A Market Segments
After Hours
-0.03(-0.22%)
| Open | $13.65 |
|---|---|
| Close | $13.62 |
| Low | $13.40 |
| Low Change | -0.25 (-1.83%) |
| High | $13.90 |
| High Change | +0.25 (+1.83%) |
| Range | $0.50 |
| Volume | 16.079K |
| Dollar Volume | $219.00K |
Regular Trading Hours
-0.79(-5.47%)
| Open | $14.44 |
|---|---|
| Close | $13.65 |
| Low | $13.62 |
| Low Change | -0.83 (-5.71%) |
| High | $14.61 |
| High Change | +0.17 (+1.18%) |
| Range | $1.00 |
| Volume | 108.59K |
| Dollar Volume | $1.48M |
Premarket
*No Trades in Segment
After Hours Yesterday
*No Trades in Segment
Regular Trading Hours Yesterday
-0.07(-0.48%)
| Open | $14.61 |
|---|---|
| Close | $14.54 |
| Low | $14.31 |
| Low Change | -0.30 (-2.05%) |
| High | $14.89 |
| High Change | +0.28 (+1.92%) |
| Range | $0.58 |
| Volume | 108.12K |
| Dollar Volume | $1.57M |
Premarket Yesterday
*No Trades in Segment
Contineum Therapeutics Class A Moving Averages
| 5 Day Moving Average (SMA5) | $14.53 |
|---|---|
| 10 Day Moving Average (SMA10) | $13.62 |
| 20 Day Moving Average (SMA20) | $13.32 |
| 50 Day Moving Average (SMA50) | $13.34 |
| 100 Day Moving Average (SMA100) | $13.17 |
| 200 Day Moving Average (SMA200) | $11.71 |
Contineum Therapeutics Class A Statistics
| Average Volume (30 Days) | 253.89K |
|---|---|
| P/E Ratio (Current) | -9.38 |
| EPS (Current) | -$1.56 |
| Dividend Yield | 0.00% |
| Free Cash Flow | -$57.66M |
| Cash Ratio | 3.03 |
| Current Ratio | 38.00 |
| Quick Ratio | 38.00 |
| Debt to Equity | 0.00 |
| Enterprise Value | $526.80M |
| EV to EBITDA | -7.92 |
| EV to Sales | — |
| Price to Book | 2.19 |
| Price to Cash Flow | — |
| Price to Free Cash Flow | — |
| Price to Sales | — |
| Return on Assets | -0.22% |
| Return on Equity | -0.23% |
Contineum Therapeutics Class A Stock Splits
There have been no stock splits for Contineum Therapeutics Class A (CTNM).
Contineum Therapeutics Class A Dividends
There have been no dividends for Contineum Therapeutics Class A (CTNM).